Change in the Roche Board of Directors
Roche (OTCQX: RHHBY) announced on 3 October 2025 that Dr. Claudia Süssmuth Dyckerhoff will not stand for re-election to the Roche Board at the 2026 Annual General Meeting. She has served on Roche's Board since March 2016 and will be nominated for election to the board of another company in the healthcare industry. Chairman Severin Schwan thanked her for a decade of contributions, citing her knowledge of healthcare and international market dynamics, particularly in Asia.
Roche (OTCQX: RHHBY) ha annunciato il 3 ottobre 2025 che Dott.ssa Claudia Süssmuth Dyckerhoff non si ricandiderà al consiglio di Roche all'Assemblea Generale Annuale 2026. Ha fatto parte del consiglio di Roche dal marzo 2016 e sarà nominata per l'elezione al consiglio di un'altra azienda nel settore sanitario. Il presidente Severin Schwan l'ha ringraziata per un decennio di contributi, citando la sua conoscenza del settore sanitario e delle dinamiche dei mercati internazionali, in particolare in Asia.
Roche (OTCQX: RHHBY) anunció el 3 de octubre de 2025 que la Dra. Claudia Süssmuth Dyckerhoff no se presentará a la reelección del Consejo de Roche en la Junta General Anual 2026. Ha formado parte del Consejo desde marzo de 2016 y será nominada para ser elegida en el consejo de otra empresa del sector sanitario. El presidente Severin Schwan le agradeció una década de aportes, citando su conocimiento del sector sanitario y de las dinámicas de los mercados internacionales, particularmente en Asia.
Roche (OTCQX: RHHBY)은 2025년 10월 3일에 Dr. Claudia Süssmuth Dyckerhoff가 2026년 정기 주주총회에서 로슈 이사회 재선에 출마하지 않겠다고 발표했다. 그녀는 2016년 3월부터 로슈 이사회에서 재임해 왔으며, 보건의료 산업의 다른 회사 이사회 선임을 위해 지명될 예정이다. 의장 Severin Schwan은 10년 간의 기여에 대해 그녀의 의료 분야 지식과 국제 시장 역학, 특히 아시아를 언급하며 감사를 표했다.
Roche (OTCQX: RHHBY) a annoncé le 3 octobre 2025 que Dr. Claudia Süssmuth Dyckerhoff ne se présentera pas à la retraite du conseil de Roche lors de l'Assemblée générale annuelle 2026. Elle siège au conseil de Roche depuis mars 2016 et sera nommée pour être élue au conseil d'une autre société du secteur des soins de santé. Le président Severin Schwan l'a remerciée pour une décennie de contributions, citant sa connaissance du secteur de la santé et des dynamiques des marchés internationaux, en particulier en Asie.
Roche (OTCQX: RHHBY) gab am 3. Oktober 2025 bekannt, dass Dr. Claudia Süssmuth Dyckerhoff sich bei der Hauptversammlung 2026 nicht erneut für den Roche-Vorstand kandidieren wird. Sie ist seit März 2016 Mitglied des Roche-Vorstands und wird für eine Wahl in den Vorstand eines anderen Unternehmens im Gesundheitswesen nominiert werden. Vorsitzender Severin Schwan dankte ihr für ein Jahrzehnt an Beiträge und hob ihr Wissen im Gesundheitswesen sowie die Dynamik der internationalen Märkte, insbesondere in Asien, hervor.
Roche (OTCQX: RHHBY) أعلنت في 3 أكتوبر 2025 أن الدكتورة كلاوديا سُسـموت دِيكهورف لن تتقدم لإعادة انتخابها لعضوية مجلس Roche في اجتماع الجمعية العمومية السنوي 2026. لقد شغلت مقعدها في مجلس Roche منذ مارس 2016 وستُرشَّح للانتخاب في مجلس إدارة شركة أخرى في قطاع الرعاية الصحية. وشكر الرئيس Severin Schwan لها على عقد من المساهمات، مع الإشارة إلى معرفتها بقطاع الرعاية الصحية وت dynamique الأسواق الدولية، ولا سيما في آسيا.
Roche (OTCQX: RHHBY) 于 2025年10月3日 公告，克劳迪娅·苏斯穆特·迪克豪夫博士 将不再竞选罗氏董事会，参加<2026年度股东大会。她自 2016年3月 起担任罗氏董事会成员，并将被提名在另一家医疗保健行业公司的董事会任职。董事长 Severin Schwan 对她十年的贡献表示感谢，指出她在医疗保健领域的知识以及对国际市场动态，尤其是亚洲的理解。
- None.
- None.
Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Dr. Claudia Süssmuth Dyckerhoff has decided not to stand for re-election as a member of the Roche Board of Directors at the Annual General Meeting in 2026. Instead she will be nominated for election to the board of another company which is serving the healthcare industry.
Dr. Süssmuth Dyckerhoff has served on the Board of Directors since March 2016.
Roche Chairman Severin Schwan: "Claudia’s profound knowledge of the healthcare industry and her deep understanding of international market dynamics, particularly in Asia, have resulted in significant contributions to the success of Roche. On behalf of the Board, I would like to sincerely thank Claudia for her dedication to Roche over the past decade and wish her all the best for the future.”
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
| Hans Trees, PhD Phone: +41 79 407 72 58 | Sileia Urech Phone: +41 79 935 81 48 |
| Nathalie Altermatt Phone: +41 79 771 05 25 | Lorena Corfas Phone: +41 79 568 24 95 |
| Simon Goldsborough Phone: +44 797 32 72 915 | Karsten Kleine Phone: +41 79 461 86 83 |
| Kirti Pandey Phone: +49 172 6367262 | Yvette Petillon Phone: +41 79 961 92 50 |
| Dr Rebekka Schnell Phone: +41 79 205 27 03 |
Attachment
FAQ
Who announced the board change for Roche (RHHBY) on October 3, 2025?
When will Dr. Claudia Süssmuth Dyckerhoff leave the Roche board (RHHBY)?
How long has Dr. Claudia Süssmuth Dyckerhoff served on Roche's board (RHHBY)?
Will Dr. Claudia Süssmuth Dyckerhoff join another company after leaving Roche (RHHBY)?
Did Roche provide a reason or comment on Dr. Süssmuth Dyckerhoff's departure (RHHBY)?
Does the October 3, 2025 Roche (RHHBY) release indicate any immediate financial impact?
